Clarient Licenses HDC's Prostate Cancer Marker for Dx Commercialization | GenomeWeb
NEW YORK (GenomeWeb News) - Clarient has acquired an exclusive license to Health Discovery Corporation’s prostate cancer marker and plans to develop and commercialize a test based on the marker, HDC said today.
 
Under the agreement, HDC will receive a 30 percent royalty payment for all prostate cancer tests Clarient performs for third parties using the technology.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.